None listed
Conditions
Brief summary
The aim of the project is to test whether giving a medication called desferrioxamine (commonly used in patients with iron-overload conditions such as beta-thalassaemia) in the setting of a heart attack can reduce the amount of heart muscle injury. We hypothesise that that this medication may therefore improve the outlook for people following heart attacks. This medication has been used safely in adults and children with beta thalassaemia at even higher doses. This drug has been shown in experimental, animal and a few human studies to reduce the “oxidative stress” (that is, acts as an “antioxidant”) of tissues which have had their blood supply compromised (as in the case of a heart attack). Some of the animal studies have also shown that it reduces the size of heart attacks.
Interventions
Intravenous desferrioxamine; 500mg IV bolus over 10 minutes followed by 50mg/kg infusion over 12 hours
Sponsors
The Alfred Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Suspected ST-segment Elevation Myocardial Infarction (STEMI) < 6 hours duration (from symptom onset) defined by detection of rise and/or fall of cardiac biomarkers (troponin and CK) with at least one value above the 99th percentile of the upper reference limit together with evidence of ischemia with at least one of the following: - Symptoms of ischemia - Electrocardiographic (ECG) changes of new ischemia (new ST-T elevation or new left bundle branch block [LBBB]) and/or development of new pathological Q waves in the ECG - New ST elevation at the J point = 0.2 mV in men or = 0.15 mV in women in V2-V3; and/or = 0.1 mV in other leads in both genders
Exclusion criteria
1) Permanent pacemaker, implantable cardiac defibrillator, or other metallic prosthesis (ineligible for CMRI) 2) Suspected previous myocardial infarction in the same coronary artery territory as the current STEMI 3) Rescue angioplasty post-thrombolytics 4) Cardiogenic shock (systolic blood pressure <90mmHg whether or not inotropic support is required) 5) Currently pregnant 6) Known malignancy 7) Known infection 8) Current iron supplementation or known iron deficient state 9) Renal failure (estimated glomerular filtration rate less than or equal to 30ml/min, defined by the Cockroft-Gault formula 10) Thrombocytopenia (platelets <50) 11) Neutropenia 12) Known hypersensitivity to desferrioxamine 13) Unwilling to consent 14) Non-English speaking
Outcome results
None listed